All In Biotech

Drug Trial Radar · NCT07492680

A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

A Phase 2 Open-Label, Multi-Center Study of Navlimetostat (BMS-986504) as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTap-5)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

254

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Aug 15, 2028

Study completion May 20, 2032

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which Navlimetostat (BMS-986504) is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Navlimetostat (BMS-986504) alone and in combination regimens.

Conditions

  • Solid Tumors

Interventions

  • NavlimetostatDrug

    Specified dose on specified days

  • DaraxonrasibDrug

    Specified dose on specified days

  • TemozolomideDrug

    Specified dose on specified days

  • PumitamigDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • Nab-paclitaxelDrug

    Specified dose on specified days

  • GemcitabineDrug

    Specified dose on specified days

  • PaclitaxelDrug

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants who achieve Objective Response (OR)Time frame: Up to approximately 2 years
  2. Part 2: Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteriaTime frame: Up to approximately 2 years
  3. Part 2: Number of participants with adverse events (AE)Time frame: Up to approximately 2 years
  4. Part 2: Number of participants with Serious AEs (SAEs)Time frame: Up to approximately 2 years
  5. Part 2: Number of participants with treatment related AEsTime frame: Up to approximately 2 years
  6. Part 2: Number of participants with treatment related SAEsTime frame: Up to approximately 2 years
  7. Part 2: Number of participants with AEs leading to study treatment discontinuationTime frame: Up to approximately 2 years
  8. Part 2: Number of participants with AEs leading to deathTime frame: Up to approximately 2 years
  9. Part 2: Number of participants with laboratory abnormalitiesTime frame: Up to approximately 2 years

Locations

58 sites in 13 countries. Site status is shown where the registry gives one.

  • Local Institution - 0096

    San Francisco, California · Not yet recruiting

  • Local Institution - 0182

    Aurora, Colorado · Not yet recruiting

  • Emory University - Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Local Institution - 0124

    Boston, Massachusetts · Not yet recruiting

  • Local Institution - 0119

    Ann Arbor, Michigan · Not yet recruiting

  • Local Institution - 0129

    Rochester, Minnesota · Not yet recruiting

  • Local Institution - 0174

    Rochester, Minnesota · Not yet recruiting

  • Local Institution - 0181

    Rochester, Minnesota · Not yet recruiting

  • Local Institution - 0142

    Buffalo, New York · Not yet recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Local Institution - 0100

    Durham, North Carolina · Not yet recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Local Institution - 0086

    Seattle, Washington · Not yet recruiting

  • Local Institution - 0134

    Madison, Wisconsin · Not yet recruiting

  • UZ Brussel

    Brussels, Bruxelles-Capitale, Région de, Belgium · Recruiting

  • Cliniques universitaires Saint-Luc

    Brussels, Bruxelles-Capitale, Région de, Belgium · Recruiting

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Local Institution - 0051

    Vancouver, British Columbia, Canada · Not yet recruiting

  • Local Institution - 0021

    Toronto, Ontario, Canada · Not yet recruiting

  • Local Institution - 0007

    Toronto, Ontario, Canada · Not yet recruiting

  • Local Institution - 0155

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Local Institution - 0184

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Henan Medical University

    Xinxiang, Henan, China · Recruiting

  • Shanghai GoBroad Cancer Hospital China Pharmaceutical University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Hôpital Saint-Louis

    Paris, France · Recruiting

  • Centre Georges François Leclerc

    Dijon, Côte-d'Or, France · Recruiting

  • Local Institution - 0075

    Pierre-Bénite, Rhône, France · Not yet recruiting

  • Local Institution - 0116

    Villejuif, Val-de-Marne, France · Not yet recruiting

  • Universitaetsklinikum Hamburg

    Hamburg, Germany · Recruiting

  • Local Institution - 0039

    Heidelberg, Germany · Not yet recruiting

  • Universitaetsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Germany · Recruiting

  • Klinikum Rechts der Isar der Technischen Universitaet Muenchen

    München, Germany · Recruiting

  • Universitaetsklinikum Wuerzburg

    Würzburg, Germany · Recruiting

  • Local Institution - 0150

    Hksar, Hong Kong · Not yet recruiting

  • Local Institution - 0063

    Shatin, Hong Kong · Not yet recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.